Phillip J. Minnick

Phillip J. Minnick is an attorney at Knobbe, Martens, Olson & Bear, LLP, where he is an associate. His practice primarily focuses on intellectual property, with a strong emphasis on biotechnology, agrotechnology, and medical device and therapeutics arts. He handles matters involving diagnostics, stem cell technologies, next-generation sequencing, and large molecule therapeutics, including antibodies and protein engineering.

Minnick’s litigation experience includes representing plaintiffs in patent disputes. He appeared as counsel for Dr. Falk Pharma GmbH in a patent litigation against Ellodi Pharmaceuticals, L.P. The underlying technology in this case involved orally administered corticosteroid compositions, specifically orally disintegrating tablets for treating eosinophilic esophagitis.

He is also active in post-grant proceedings before the Patent Trial and Appeal Board (PTAB). He represented Dr. Falk Pharma GmbH as the petitioner in Inter Partes Review (IPR) proceedings, including IPR2025-00054 and IPR2024-01197, challenging patents related to orally administered corticosteroid compositions.

Minnick earned his J.D. from the University of Houston in 2023. He holds a Ph.D. in Biochemistry & Molecular Biology from Baylor College of Medicine (2019) and a B.S. in Biochemistry & Molecular Biology from Missouri Western State University (2012). He is admitted to practice in California and before the U.S. Patent and Trademark Office.